Latest news with #TrinityLifeSciences
Yahoo
a day ago
- Business
- Yahoo
Trinity Life Sciences Unveils Critical Insights for Navigating the Path From Initial Generative AI Adoption to Full-Scale Transformation
New Technical White Paper Highlights Five Essential Questions for Life Sciences Companies as Generative AI Grows and Evolves WALTHAM, Mass., June 04, 2025--(BUSINESS WIRE)--Trinity Life Sciences, the leader in advisory, insights and analytics for the life sciences industries, discusses the journey to achieving successful transformation with generative AI (GenAI) in a new white paper, entitled Technology with a Point of View: Encoding Life Sciences Expertise with AI. GenAI is a technological disruption with significant potential to revolutionize biopharmaceutical commercialization across functions and use cases by: Changing how life sciences companies find, organize and use the reams of information they handle every day Measurably improving the speed of developing insights and reducing duplicative work Handling complex data and generating sophisticated outputs GenAI can be highly effective—and it can also create frustration and disappointment when deployed ineffectively. Public failures of hastily built and deployed GenAI illustrate the pitfalls of using models that are inadequately trained, trained on low-quality data sets or developed without sufficient subject matter expertise. Technology with a Point of View: Encoding Life Sciences Expertise with AI lays out five key questions life sciences leaders should consider as they look at GenAI adoption expansion from a practical perspective: When is best to launch a new GenAI solution? Should the solution be created from scratch or through partnership with a vendor? What should we be trying to optimize with GenAI? Where do we find ROI? How do we build a data foundation for GenAI? "GenAI has groundbreaking potential in terms of business value, as it amplifies the capacity of non-technical personas within life sciences organizations to deliver exponential impact," said Rajeev Rangachari, Chief Technology Officer at Trinity Life Sciences. "Use cases that weren't viable in the past due to cost or capability limitations have begun gaining traction for specific functions within life sciences, such as Medical Affairs, Value and Access, or Field Sales." "To unlock the transformative opportunity of GenAI, two elements need to connect: leadership that imagines possibilities across business and technical worlds, and applications that bring the potential of AI to business needs," added Jonathan Jenkins, Head of Digital & AI Solutions at Trinity Life Sciences. Life sciences executives are welcome to download the white paper here. About Trinity Life Sciences With almost 30 years of expertise, a best-in-the-business team and unrivaled access to data and analytics, Trinity Life Sciences is a modern partner to companies in the life sciences industry. Trinity combines strategy, insights and analytics to help life science executives with clinical and commercial decision-making. Ultimately, we know that every decision our clients make impacts a life, and when we help our clients achieve their goals, the world benefits. To learn more about how Trinity is elevating the industry and driving evidence to action, visit View source version on Contacts Media Contact: Michele WlodarczykTrinity Life Sciencesmwlodarczyk@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
a day ago
- Business
- Associated Press
Trinity Life Sciences Unveils Critical Insights for Navigating the Path From Initial Generative AI Adoption to Full-Scale Transformation
WALTHAM, Mass.--(BUSINESS WIRE)--Jun 4, 2025-- Trinity Life Sciences , the leader in advisory, insights and analytics for the life sciences industries, discusses the journey to achieving successful transformation with generative AI (GenAI) in a new white paper, entitled Technology with a Point of View: Encoding Life Sciences Expertise with AI . This press release features multimedia. View the full release here: A technical white paper from Trinity Life Sciences, Technology with a Point of View: Encoding Life Sciences Expertise with AI, discusses the journey to achieving successful transformation with generative AI. (Graphic: Trinity Life Sciences) GenAI is a technological disruption with significant potential to revolutionize biopharmaceutical commercialization across functions and use cases by: Changing how life sciences companies find, organize and use the reams of information they handle every day Measurably improving the speed of developing insights and reducing duplicative work Handling complex data and generating sophisticated outputs GenAI can be highly effective—and it can also create frustration and disappointment when deployed ineffectively. Public failures of hastily built and deployed GenAI illustrate the pitfalls of using models that are inadequately trained, trained on low-quality data sets or developed without sufficient subject matter expertise. Technology with a Point of View: Encoding Life Sciences Expertise with AI lays out five key questions life sciences leaders should consider as they look at GenAI adoption expansion from a practical perspective: When is best to launch a new GenAI solution? Should the solution be created from scratch or through partnership with a vendor? What should we be trying to optimize with GenAI? Where do we find ROI? How do we build a data foundation for GenAI? 'GenAI has groundbreaking potential in terms of business value, as it amplifies the capacity of non-technical personas within life sciences organizations to deliver exponential impact,' said Rajeev Rangachari , Chief Technology Officer at Trinity Life Sciences. 'Use cases that weren't viable in the past due to cost or capability limitations have begun gaining traction for specific functions within life sciences, such as Medical Affairs, Value and Access, or Field Sales.' 'To unlock the transformative opportunity of GenAI, two elements need to connect: leadership that imagines possibilities across business and technical worlds, and applications that bring the potential of AI to business needs,' added Jonathan Jenkins , Head of Digital & AI Solutions at Trinity Life Sciences. Life sciences executives are welcome to download the white paper here . About Trinity Life Sciences With almost 30 years of expertise, a best-in-the-business team and unrivaled access to data and analytics, Trinity Life Sciences is a modern partner to companies in the life sciences industry. Trinity combines strategy, insights and analytics to help life science executives with clinical and commercial decision-making. Ultimately, we know that every decision our clients make impacts a life, and when we help our clients achieve their goals, the world benefits. To learn more about how Trinity is elevating the industry and driving evidence to action, visit . View source version on CONTACT: Media Contact: Michele Wlodarczyk Trinity Life Sciences [email protected] KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: RESEARCH PROFESSIONAL SERVICES PHARMACEUTICAL DATA MANAGEMENT TECHNOLOGY ARTIFICIAL INTELLIGENCE HEALTH TECHNOLOGY DATA ANALYTICS SCIENCE BIOTECHNOLOGY OTHER SCIENCE HEALTH SOURCE: Trinity Life Sciences Copyright Business Wire 2025. PUB: 06/04/2025 08:37 AM/DISC: 06/04/2025 08:36 AM
Business Wire
a day ago
- Business
- Business Wire
Trinity Life Sciences Unveils Critical Insights for Navigating the Path From Initial Generative AI Adoption to Full-Scale Transformation
WALTHAM, Mass.--(BUSINESS WIRE)-- Trinity Life Sciences, the leader in advisory, insights and analytics for the life sciences industries, discusses the journey to achieving successful transformation with generative AI (GenAI) in a new white paper, entitled Technology with a Point of View: Encoding Life Sciences Expertise with AI. GenAI is a technological disruption with significant potential to revolutionize biopharmaceutical commercialization across functions and use cases by: Changing how life sciences companies find, organize and use the reams of information they handle every day Measurably improving the speed of developing insights and reducing duplicative work Handling complex data and generating sophisticated outputs GenAI can be highly effective—and it can also create frustration and disappointment when deployed ineffectively. Public failures of hastily built and deployed GenAI illustrate the pitfalls of using models that are inadequately trained, trained on low-quality data sets or developed without sufficient subject matter expertise. Technology with a Point of View: Encoding Life Sciences Expertise with AI lays out five key questions life sciences leaders should consider as they look at GenAI adoption expansion from a practical perspective: When is best to launch a new GenAI solution? Should the solution be created from scratch or through partnership with a vendor? What should we be trying to optimize with GenAI? Where do we find ROI? How do we build a data foundation for GenAI? 'GenAI has groundbreaking potential in terms of business value, as it amplifies the capacity of non-technical personas within life sciences organizations to deliver exponential impact,' said Rajeev Rangachari, Chief Technology Officer at Trinity Life Sciences. 'Use cases that weren't viable in the past due to cost or capability limitations have begun gaining traction for specific functions within life sciences, such as Medical Affairs, Value and Access, or Field Sales.' 'To unlock the transformative opportunity of GenAI, two elements need to connect: leadership that imagines possibilities across business and technical worlds, and applications that bring the potential of AI to business needs,' added Jonathan Jenkins, Head of Digital & AI Solutions at Trinity Life Sciences. Life sciences executives are welcome to download the white paper here. About Trinity Life Sciences With almost 30 years of expertise, a best-in-the-business team and unrivaled access to data and analytics, Trinity Life Sciences is a modern partner to companies in the life sciences industry. Trinity combines strategy, insights and analytics to help life science executives with clinical and commercial decision-making. Ultimately, we know that every decision our clients make impacts a life, and when we help our clients achieve their goals, the world benefits. To learn more about how Trinity is elevating the industry and driving evidence to action, visit
Business Wire
29-05-2025
- Business
- Business Wire
Trinity Life Sciences Expands Data Partnership Network to Revolutionize Commercialization in Community Oncology
BUSINESS WIRE)-- Trinity Life Sciences, a leader in advisory, insights and analytics for the life sciences industries, announces a strategic collaboration with Ontada, a McKesson business and leader in community oncology real-world data, clinical education and point-of-care technologies. This relationship will provide life sciences companies with real-time, actionable intelligence and critical insights to drive strategic decisions both pre- and post-product launch. Together, the alliance harnesses Trinity's innovative commercial analytics methods and expertise with Ontada's iKnowMed ®, their proprietary electronic health record (EHR) with unique, deep and multi-dimensional oncology data, to rapidly uncover novel commercial insights. These insights can be leveraged to drive smarter decisions and better outcomes, ultimately enabling a transformation in the way life sciences companies make commercial decisions. Through deep understanding of the community oncology patients and providers, the collaborative solutions: - provide more powerful patient journeys and provider segmentation, - allow for increased speed and accuracy in forecasting, - and drive enhanced customer engagement and targeting. 'Understanding community oncology presents a particular challenge for commercial teams as they work to develop strategies and deploy resources to maximize adoption of life-saving therapies,' said Leslie Orne, President and CEO of Trinity Life Sciences. 'Ontada's data, coupled with Trinity's analytical services, allows the extraction of deeper, more actionable insights and powers more impactful commercial decision-making that will help to optimize patient outcomes.' Trinity's oncology expertise and depth across areas such as forecasting, real-world analytics and primary market research (PMR) allows for distinctive, AI-enhanced approaches that provide ever-greater insight into key business questions to assess potential outcomes. Trinity offers innovative solutions built for life sciences' unique needs, scaling transformational AI and tech-enabled programs across functions with a focus on customer engagement, launch, medical affairs and GenAI. 'The need for rapid insights in cancer care has never been greater. Ontada's collaboration with Trinity demonstrates our commitment to delivering faster answers to critical questions. By connecting Trinity's robust analytics with Ontada's nuanced and unique data sets, we can provide deeper, more actionable insights for our life science partners,' said Christine Davis, President of Ontada. 'Speed is crucial not only to our life science partners but also for cancer patients, who can benefit greatly from a better understanding of precision therapies.' Ontada's real-world data provides comprehensive insights throughout the patient journey and a unique view of community cancer care. It represents data from more than 2.4 million patient records across over 80 tumor types from The US Oncology Network and Onmark practices. Ontada's iKnowMed ® is an award winning EHR used by more than 2,400 oncology community-based providers across the United States, dedicated to advancing local cancer care and better patient outcomes. To learn more about this collaboration, visit Trinity Life Sciences and Ontada (at Ontada's booth 35093) at ASCO. About Trinity Life Sciences With almost 30 years of expertise, a best-in-the-business team and unrivaled access to data and analytics, Trinity Life Sciences is a modern partner to companies in the life sciences industry. Trinity combines strategy, insights and analytics to help life science executives with clinical and commercial decision-making. Ultimately, we know that every decision our clients make impacts a life, and when we help our clients achieve their goals, the world benefits. To learn more about how Trinity is elevating the industry and driving evidence to action, visit
Yahoo
06-05-2025
- Business
- Yahoo
Trinity Life Sciences Announces Winners of TGaS Advisors Best of Benchmark Awards for Operational Excellence in Pharma Industry
The Best of Benchmark Awards are given annually for operational excellence within the pharmaceutical industry. (Photo: Trinity Life Sciences) AbbVie, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson Among Honorees for Exceptional Performance in Pharmaceutical Operations, Recognized as Industry Leaders by TGaS Division WALTHAM, Mass., May 06, 2025--(BUSINESS WIRE)--Trinity Life Sciences, the leader in strategy, insights and analytics for the life sciences industry, announces the winners of the TGaS Advisors Best of Benchmark (BoB) Awards. The awards, which are given annually for operational excellence within the pharmaceutical industry, were presented to teams at AbbVie, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson Innovative Medicine, Neurocrine Biosciences, Novartis, Pharmacosmos Therapeutics, Sage Therapeutics and Sarepta Therapeutics. The BoBs are based on TGaS benchmarking of large, midsize and emerging life sciences companies. While the specific BoB criteria subtly change from function to function, the underlying factor for recognition is a pharma operations team that demonstrates the best capability relative to peers in the industry for a specific department, function or process. Winners are chosen based on TGaS benchmarks executed within the prior two calendar years, which gives the TGaS Division a deep understanding of all eligible clients. "Operations teams play a critical role in pharmaceutical organizations, yet they often go unnoticed as the 'unsung heroes' in the industry," said Gary McWalters, President, TGaS Advisors, a Division of Trinity Life Sciences. "We are thrilled to acknowledge and celebrate these exceptional teams and the winning companies who have demonstrated superior capabilities that set them apart from their peers. Congratulations to all the winners on their well-deserved recognition." Eighth Annual Best of Benchmark Award Winners:
